More Weakness Ahead For Biotechnology Stocks

Biotechnology stocks had a great run over the past few years but likely got ahead of themselves early this year. The current mean-reversion move to the downside in biotechnology stocks looks feels heavier and looks to have more to go. Here is how I am measuring the downside targets.

Serge Berger

Submit a Comment

Your email address will not be published.


Your ultimate source of knowledge about the markets.

Recent Posts

Get Our Free Daily Trading Videos

Delivered To your Inbox

By submitting your information you agree to our Terms of Service and our Privacy Policy